bioRxivNeurosciencePreprint
Screening of a kinase inhibitor library in human Huntington disease iPSC derived striatal precursor neurons reveals a neuroprotective effect of PKC alpha and PKC beta1 inhibition
Mali JiangiD, Tianze ShiiD, Ritika MiryalaiD, Matthew RodrigueziD, Ronald S. WangiD, Rashi Sultania, Lauren C. GuttmaniD, Julia Johnston, Louisa Mulligan, Yushan LiiD, Anning Cui, Karim Belkas, Yuxuan Xue, Yuna Um, Amy Yuan, Chloe D. Holland, Juan Carlos TroncosoiD, Wenzhen DuaniD, Tamara RatovitskiiD, Wanli Wei SmithiD, Christopher A. RossiD
- Citations
- 0
Abstract
The loss of striatal medium spiny neurons is a hallmark of Huntingtons disease (HD). To identify potential disease-modifying treatments, we previously developed a human neuronal model by immortalizing and differentiating HD patient-derived iPSCs into highly homogeneous striatal precursor neurons (ISPNs). Using a 96-well screening platform, and two rounds of re-screening, we tested a kinase inhibitor library and identified 5 compounds that protected HD ISPNs from mutant huntingtin (mHTT)-induced toxicity. Among these, we prioritized the PKC-/{beta}1 inhibitor GO6976, which rescued HD ISPNs from mHTT toxicity in a dose-dependent manner. Further, we found increased phosphorylation of PKC- and PKC-{beta}1 in HD cells and tissues, while their overexpression was toxic to HD ISPNs. Knockdown of PKC-/{beta}1 protected the neurons, and both isoforms interacted and colocalized with HTT. These results suggest that PKC-/{beta}1 plays a role in HD neurodegeneration, and that inhibiting their activity may offer a potential therapeutic approach for HD. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=194 SRC="FIGDIR/small/677178v2_ufig1.gif" ALT="Figure 1"> View larger version (48K): org.highwire.dtl.DTLVardef@256d6org.highwire.dtl.DTLVardef@1931e7borg.highwire.dtl.DTLVardef@1b6598borg.highwire.dtl.DTLVardef@b0bbb5_HPS_FORMAT_FIGEXP M_FIG C_FIG HighlightsO_LIHD patient-derived iPSC-based striatal precursor neurons (ISPNs) were used to screen and identify neuroprotective compounds. C_LIO_LIThe PKC-/{beta}1 inhibitor GO6976 rescues HD ISPNs from mutant huntingtin (HTT)-induced toxicity. C_LIO_LIThe phosphorylation of PKC-/{beta}1 is elevated in HD cell and tissues, and PKC-/{beta}1 interact with both wild-type and mutant huntingtin. C_LIO_LIOverexpression of PKC-/{beta}1 is toxic to HD ISPNs, while its knockdown protects the neurons. C_LI
- organism: human
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Human striatal progenitor cells that contain inducible safeguards and overexpress BDNF rescue Huntington's disease phenotypes in R6/2 mice
Danielle A. Simmons, Sridhar Selvaraj, … Frank M. Longo·Molecular Therapy — Methods & Clinical DevelopmentPeer-reviewed·Jan 22, 2025
- High Content Screening and Proteomic Analysis Identify a Kinase Inhibitor that rescuespathological phenotypes in a Patient-Derived Model of Parkinson's Disease
Nasia Antoniou, Kanella Prodromidou, … Rebecca Matsas·npj Parkinson s DiseasePeer-reviewed·Feb 11, 2022
- Lowering mutant huntingtin by small molecules relieves Huntington's disease symptoms and progression
Anat Bahat, Elad Itzhaki, … Rivka Dikstein·EMBO Molecular MedicinePeer-reviewed·Feb 19, 2024
- Protective role of Pten downregulation in Huntington's Disease models
Nisha Nisha, Deepti Thapliyal, … Mayanglambam Dhruba Singh·bioRxiv·Mar 28, 2024
- Striatal neuron excitability is regulated by huntingtin in the adult brain
Jessica C. Barron, Meghan L. Greenland, … Matthew P. Parsons·eNeuroPeer-reviewed·May 28, 2026
- In vivo progressive degeneration of Huntington's disease patient-derived neurons reveals human-specific pathological phenotypes
Andrés Miguez, Sara Fernández‐García, … Josep Maria Canals·bioRxiv·Oct 21, 2020